Therefore, the ability of TRPM2 inhibition to enhance cytotoxicity in TN and ER+ breast adenocarcinoma cells suggests that targeting TRPM2 may provide improved treatment options for TN and ER+ breast cancer patients in the future. Here, TRPM2 is linked to breast carcinoma.